コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 eater solution stability than alpha-methyl-5-hydroxytryptamine.
3 ibroblast growth factor receptor 1 (FGFR1)-5-hydroxytryptamine 1A (5-HT1A) receptor complexes have be
4 altered through serotonergic modulation of 5-hydroxytryptamine 1A (5-HT1A) receptors, which hyperpola
6 agonist radioligand for the serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptor in recombinant c
7 cross arousal states are affected when the 5-hydroxytryptamine 1A receptor (5-HT1A) agonist (R)-(+)-8
8 ivation of G(i), by comparing Smo with the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor, a quintessent
10 measurement of activation of the serotonin 5-hydroxytryptamine-1A (5-HT(1A)) receptor expressed in CH
12 evidence implicates the serotonin receptor 5-hydroxytryptamine 1B (5-HT1B) in the effects of cocaine.
14 y that GSK3beta selectively interacts with 5-hydroxytryptamine-1B receptors (5-HT1BR) that have impor
16 led as a GPCR heteromer with the serotonin 5-hydroxytryptamine 2A (5-HT(2A)) receptor in the mouse fr
24 ibosomal S6 kinase 2 (RSK2) interacts with 5-hydroxytryptamine(2A) (5-HT(2A)) serotonin receptors and
27 s suggest that cis-UCA binds to serotonin (5-hydroxytryptamine) 2A (5-HT(2A)) receptor and that antag
28 ocked by SB742457 but not by the selective 5-hydroxytryptamine-2A (5HT2A) antagonist ketanserin) and
29 on the postsynaptic serotonin-2A receptor (5-hydroxytryptamine-2A, or 5-HT2A) status were investigate
30 n structure of a complex between the human 5-hydroxytryptamine 2B (5-HT2B) receptor and an antibody F
31 ssessed whether these polymorphisms affect 5-hydroxytryptamine 2B (5-HT2B) receptor in vitro pharmaco
32 atory function requires stimulation of the 5-hydroxytryptamine 2B receptor (5-HT(2B)) on HSCs by sero
34 intensity arising from fluorescence-tagged 5-hydroxytryptamine 2C (5-HT(2C)) receptors diffusing with
35 press an eGFP-tagged form of the serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor, global analysis
40 hod is based on the serotonin 2C receptor (5-hydroxytryptamine(2C); 5HT(2C)) transcript, an RNA editi
44 ] receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 [5-HT3] receptor antagonist) for the
45 management up to 72 h with the long-acting 5-hydroxytryptamine-3 receptor antagonist palonosetron.
48 sensory cortex of the mouse, the serotonin 5-hydroxytryptamine 3A (5-HT(3A)) receptor, the only ionot
49 has greater potency at mouse than at human 5-hydroxytryptamine 3A (5-HT3A) receptors, despite 84% ami
50 main 2 (TM2) to the TM2-TM3 loop, in mouse 5-hydroxytryptamine(3A) (5-HT(3A)) receptor function was p
52 velopment of a PET radioligand for imaging 5-hydroxytryptamine (5-HT) 6 receptors in the brain would,
54 ent activated by maximal concentrations of 5-hydroxytryptamine (5-HT) and increased the magnitude of
55 ed segments of native mouse intestine with 5-hydroxytryptamine (5-HT) and prostaglandin E2 (PGE2) ind
57 gh there is general agreement that mucosal 5-hydroxytryptamine (5-HT) can initiate peristaltic reflex
58 blot, whereas tryptophan, kynurenine, and 5-hydroxytryptamine (5-HT) concentrations were quantified
61 ansport protein which re-uptakes excessive 5-hydroxytryptamine (5-HT) from effective location to term
63 (SERT) is responsible for the re-uptake of 5-hydroxytryptamine (5-HT) from the synaptic cleft after r
65 m) revealed significantly higher levels of 5-hydroxytryptamine (5-HT) in the striatum and hippocampus
66 ation of cultured smooth muscle cells with 5-hydroxytryptamine (5-HT) induced PAK1 phosphorylation at
72 ng reversal learning, whilst orbitofrontal 5-hydroxytryptamine (5-HT) likely mediates this type of lo
73 sent studies examined the acute effects of 5-hydroxytryptamine (5-HT) on NHE activity using Caco-2 ce
79 ad use of short-acting antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patients
80 for beta-arrestin signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are rela
81 tify that both ionotropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on whis
82 ced inactivation and reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant cell
84 racellular free calcium ([Ca(2+)](i)), and 5-hydroxytryptamine (5-HT) release in human carcinoid BON
85 ene (Itgb3) on SERT function and selective 5-hydroxytryptamine (5-HT) reuptake inhibitor (SSRI) effec
86 er inhibitor Prozac, the inhibition of the 5-hydroxytryptamine (5-HT) transporter by the ion channel
87 KM Apl III in the sensory neuron 2 d after 5-hydroxytryptamine (5-HT) treatment reversed persistent n
90 d Sf9 cells, we show the inhibition of [3H]5-hydroxytryptamine (5-HT) uptake and [3H]dihydrotetrabena
91 mucus release stimulated by either PGE2 or 5-hydroxytryptamine (5-HT) was approximately half that sti
94 function in vivo led to reduced serotonin (5-hydroxytryptamine (5-HT)) blood levels that paralleled a
99 pse is dynamically regulated by serotonin (5-hydroxytryptamine (5-HT)) with elevated levels leading t
100 to elevated levels of embryonic serotonin (5-hydroxytryptamine (5-HT)), and we found that knockdown o
105 Na(+) for driving transport and promoting 5-hydroxytryptamine (5-HT)-dependent conformational change
106 transporter (SERT) acting as a conduit to 5-hydroxytryptamine (5-HT)-mediated apoptosis, specificall
108 ression in golden hamsters is inhibited by 5-hydroxytryptamine (5-HT)1A receptors and facilitated by
111 at acute stressors can increase serotonin [5-hydroxytryptamine (5-HT)] concentrations in the dorsomed
112 dy of literature has implicated serotonin [5-hydroxytryptamine (5-HT)] in descending modulation of no
113 e is known about the actions of serotonin [5-Hydroxytryptamine (5-HT)] in this region during developm
117 The dynamic interplay between serotonin [5-hydroxytryptamine (5-HT)] neurotransmission and the hypo
119 oded Ile, Asn, and Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with V
120 we examined the hypothesis that serotonin [5-hydroxytryptamine (5-HT)] receptor activation enhances T
121 dence that cis-UCA binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively high
129 e foremost hypothesis of depression is the 5-hydroxytryptamine (5-HT, serotonin) deficiency hypothesi
131 th a prenatal, genetically induced loss of 5-hydroxytryptamine (5-HT, serotonin) neurones are comprom
134 have found that the serotonin 1B receptor [5-hydroxytryptamine (5-HT1B) receptor] interacts with p11.
135 was reversed by systemic treatment with a 5-hydroxytryptamine (5-HT2C) receptor agonist and mimicked
136 ssion in the central nervous system (CNS), 5-hydroxytryptamine (5-HT: serotonin) subtype 6 receptor (
137 responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic
139 ion studies suggest that variations in the 5-hydroxytryptamine (5-HT; serotonin) transporter (5-HTT)
142 were obtained for quipazine (nonselective 5-hydroxytryptamine [5-HT] agonist; 1.0-10.0 mg/kg), CGS-1
145 We tested the hypothesis that serotonin (5-hydroxytryptamine [5-HT]) exerts stimulatory and inhibit
147 suggested an important role for serotonin (5-hydroxytryptamine [5-HT]) in enhancing the counterregula
152 Bag cell neurons exposed to serotonin (5-hydroxytryptamine [5-HT]) respond with a threefold incre
153 ifferent pruritogens, including serotonin (5-hydroxytryptamine [5-HT]), histamine, SLIGRL (protease-a
158 neurotrophic factor (BDNF) and serotonin (5-hydroxytryptamine, 5-HT) are known to regulate synaptic
161 teroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubert
162 as induced by an increase in serotonergic (5-hydroxytryptamine, 5-HT) efficacy has been a target of a
163 ssociated with abnormalities in serotonin (5-hydroxytryptamine, 5-HT) in regions of the brainstem cri
165 eus (DR) is the major source of serotonin (5-hydroxytryptamine, 5-HT) in the forebrain and dysfunctio
171 g RVM neurons, we found that serotonergic (5-hydroxytryptamine, 5-HT) neurons decreased by 35% ipsila
173 ration to examine the effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmenta
174 he nuclei and expresses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including th
176 trafficking of single groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantum
177 e oxidase (MAOIs) and selective serotonin (5-hydroxytryptamine, 5-HT) reuptake (SSRIs) induces seroto
178 vesicular release, dopamine and serotonin (5-hydroxytryptamine, 5-HT) signaling is controlled by tran
184 ed mice had reduced contents of serotonin (5-hydroxytryptamine, 5-HT), a neurotransmitter involved in
185 evoked reduction in hippocampal serotonin (5-hydroxytryptamine, 5-HT), as did the 5-HT(1A) receptor a
186 act contains much of the body's serotonin (5-hydroxytryptamine, 5-HT), but mechanisms controlling the
187 In vitro data suggest that serotonin (5-hydroxytryptamine, 5-HT), via the 5-HT(2A) receptor (5-H
190 O A), the key enzyme catalyzing serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) degrada
192 e tyrosine hydroxylase (TH) and serotonin (5-hydroxytryptamine; 5-HT) immunoreactivity, in conjunctio
194 aphe nucleus, which provides serotonergic (5-hydroxytryptamine; 5-HT) innervation to the nucleus accu
198 ry is that a breakdown in brain serotonin (5-hydroxytryptamine; 5-HT) signalling is critically involv
199 Presynaptic, plasma membrane serotonin (5-hydroxytryptamine; 5-HT) transporters (SERTs) clear 5-HT
203 e source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurotra
204 e source of nearly all systemic serotonin (5-hydroxytryptamine; 5-HT), which is an important neurotra
210 its role as a neurotransmitter, serotonin (5-hydroxytryptamine, 5HT) regulates inflammation and tissu
212 ylamide (LSD) binding to recombinant human 5-hydroxytryptamine 6 (5-HT(6)) receptors expressed in Chi
214 ship (QSAR) models of compounds binding to 5-hydroxytryptamine-6 receptor (5-HT(6)R), a known target
216 -(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HT6R) antagonists result
217 e previously reported on the unusual human 5-hydroxytryptamine(7) (h5-HT(7)) receptor-inactivating pr
218 ratching was observed following i.d. 5-HT (5-hydroxytryptamine), a protease-activated receptor (PAR)-
219 that a distinct multiprotein complex links 5-hydroxytryptamine-activated intracellular signaling even
220 is responsible for reuptake of serotonin (5-hydroxytryptamine) after its exocytotic release from neu
221 ostasis, such as the melanocortin, leptin, 5-hydroxytryptamine and brain-derived neurotrophic factor
222 ed release of the peristaltic transmitters 5-hydroxytryptamine and calcitonin gene-related peptide; a
223 the pathway, the O-methylation of N-acetyl 5-hydroxytryptamine by hydroxyindole-O-methyltransferase.
224 ed by acidic citrate, but not alpha-methyl-5-hydroxytryptamine, chloroquine, compound 48/80, or bile
225 mucosal reflexes, which release serotonin (5-hydroxytryptamine) from enterochromaffin cells, and stre
226 single conformations of neutral serotonin (5-hydroxytryptamine) have been studied in the gas phase us
228 a variety of cellular signals elicited by 5-hydroxytryptamine in both peripheral and central tissues
229 lular signals elicited by serotonin (5-HT; 5-hydroxytryptamine) in both peripheral and central tissue
230 onoamine neurotransmitter serotonin (5-HT, 5-hydroxytryptamine) in the central nervous system, and dr
232 of the neurotransmitter, serotonin (5-HT; 5-hydroxytryptamine), into cells by the 5-HT transporter (
233 MAOA-L, by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry f
236 the mutant SNAP-25 could no longer support 5-hydroxytryptamine-mediated inhibition of exocytosis.
237 igated the effect of diminished serotonin (5-hydroxytryptamine) neurotransmission using dietary trypt
238 ignificantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-p
240 lectroactive chemical messenger serotonin (5-hydroxytryptamine or 5-HT) for the real-time measurement
243 ll molecules, we identified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitepin
245 tic (type III) cells to release serotonin (5-hydroxytryptamine, or 5-HT) and norepinephrine (NE).
250 not observed in response to acetylcholine, 5-hydroxytryptamine, or the protease-activated receptor-1
251 ed and produced soluble factors serotonin (5-hydroxytryptamine), platelet factor 4, and platelet-acti
253 al unfolding of a homopentameric LGIC, the 5-hydroxytryptamine receptor (ligand binding, secondary st
254 The objective of this study was to compare 5-hydroxytryptamine receptor 1A (5-HT(1A)) PET with cerebr
256 aper addresses whether the availability of 5-hydroxytryptamine receptor 1B (5-HT(1B)) is seen to decr
257 around 500 kb upstream of the locus HTR1E (5-hydroxytryptamine receptor 1E) locus, related to the ser
258 can result from the abrupt withdrawal of a 5-hydroxytryptamine receptor 2A antagonist from a treatmen
259 pa-opioid receptors or blockade of 5-HT2A (5-hydroxytryptamine receptor 2A) receptors, suppressed mot
261 on studies linking the c.68C allele of the 5-hydroxytryptamine receptor 2C gene to lower seizure risk
264 In "priming" experiments with a type 2 5-hydroxytryptamine receptor agonist, we have shown a like
265 and administration of dexamethasone and a 5-hydroxytryptamine receptor antagonist such as ondansetro
267 f the G alpha(q)-linked serotonin receptor 5-hydroxytryptamine receptor-2b (Htr2b) in maternal islets
270 tic receptors of enteric neurons, Ret, and 5-hydroxytryptamine-receptor subtypes at 33 degrees C and
271 e Y, vasoactive intestinal peptide, or the 5-hydroxytryptamine (serotonin) 3a receptor, were silent.
273 a selective, high-affinity agonist of the 5-hydroxytryptamine (serotonin) receptor 4 that enhances m
274 scent photoproducts of the hydroxyindoles, 5-hydroxytryptamine (serotonin), 5-hydroxytrptophan, and 5
275 Cl(-)-dependent transporters for dopamine, 5-hydroxytryptamine (serotonin), noradrenaline, GABA and g
276 tation (LTF) of sensory neuron synapses by 5-hydroxytryptamine (serotonin; 5-HT) requires the activat
277 y of new antiemetic medications, primarily 5-hydroxytryptamine subtype 3 receptor antagonists, as wel
281 t an influence of natural variation in the 5-hydroxytryptamine transporter (5-HTT) gene on multiple a
282 e gene encoding the serotonin transporter [5-hydroxytryptamine transporter (5-HTT)] affect the transc
283 d treatment of C6 glioma cells, which lack 5-hydroxytryptamine transporters, showed marked concentrat
284 y spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A receptors and temporally coinc
285 ansmembrane domain (M3) is conserved among 5-hydroxytryptamine type 3 (5-HT(3)) receptor subunits and
290 is article, we discuss the pharmacology of 5-hydroxytryptamine type 3 receptor antagonists and the im
291 ients may help differentiate responders to 5-hydroxytryptamine type 3 receptor antagonists from non-r
294 -binding cassette subfamily B member 1 and 5-hydroxytryptamine type 3 receptor subunits also contribu
295 y of pentameric ligand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT3Rs) are activat
296 hasone, aprepitant or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patient
297 (436) and Arg(440)) within the MA helix of 5-hydroxytryptamine type 3A (5-HT3A) receptors act singula
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。